Cancer cell membrane-camouflaged biomimetic nanoparticles for enhancing chemo-radiation therapy efficacy in glioma

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive and lethal brain tumor with limited treatment options. To improve therapeutic efficacy, we developed a novel multifunctional nanoplatform, GM@P(T/S), comprised of polymeric nanoparticles coated with GBM cell membranes as well as co-loaded with temozolomide (TMZ) and superparamagnetic iron oxide (SPIO) nanoparticles. The successful preparation was confirmed in terms of particle size, morphology, stability, the in vitro drug release, and cellular uptake assays. We demonstrated that GM@P(T/S) exhibited the enhanced homotypic targeting, the prolonged blood circulation, and efficient blood-brain barrier penetration in both in vitro and in vivo studies. The combination of TMZ and SPIO nanoparticles within GM@P(T/S) synergistically improved chemo-radiation therapy, leading to a reduced tumor growth, an increased survival, and minimal systemic toxicity in the orthotopic GBM mouse models. Our findings suggest that GM@P(T/S) holds a great promise as a targeted and efficient therapeutic strategy for GBM.

Keywords

glioblastoma multiforme / temozolomide / superparamagnetic iron oxide / chemo-radiation therapy / cancer cell membrane-coating

Fundings

This work was supported by the National Natural Science Foundation of China (Grant Nos. 82073308 and 82104089).

Acknowledgments

None.

References

[1] Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities[J]. Clin Transl Oncol, 2016, 18(11): 1062-1071. doi: 10.1007/s12094-016-1497-x

[2] Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016[J]. Neuro-Oncol, 2019, 21(S5): v1-v100. doi: 10.1093/neuonc/noz150

[3] Tan AC, Ashley DM, López GY, et al. Management of glioblastoma: state of the art and future directions[J]. CA Cancer J Clin, 2020, 70(4): 299-312. doi: 10.3322/caac.21613

[4] Khosla D. Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma[J]. Ann Transl Med, 2016, 4(3): 54. doi: 10.3978/j.issn.2305-5839.2016.01.25

[5] Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma[J]. Nat Rev Clin Oncol, 2018, 15(7): 422-442. doi: 10.1038/s41571-018-0003-5

[6] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5): 459-466. doi: 10.1016/S1470-2045(09)70025-7

[7] Rusthoven CG, Koshy M, Sher DJ, et al. Combined-modality therapy with radiation and chemotherapy for elderly patients with glioblastoma in the temozolomide era: a national cancer database analysis[J]. JAMA Neurol, 2016, 73(7): 821-828. doi: 10.1001/jamaneurol.2016.0839

[8] Goldwirt L, Beccaria K, Carpentier A, et al. Irinotecan and temozolomide brain distribution: a focus on ABCB1[J]. Cancer Chemother Pharmacol, 2014, 74: 185-193. doi: 10.1007/s00280-014-2490-0

[9] Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients[J]. Clin Cancer Res, 2004, 10(11): 3728-3736. doi: 10.1158/1078-0432.CCR-03-0807

[10] Pourgholi F, Hajivalili M, Farhad JN, et al. Nanoparticles: novel vehicles in treatment of Glioblastoma[J]. Biomed Pharmacother, 2016, 77: 98-107. doi: 10.1016/j.biopha.2015.12.014

[11] Fang C, Wang K, Stephen ZR, et al. Temozolomide nanoparticles for targeted glioblastoma therapy[J]. ACS Appl Mater Interfaces, 2015, 7(12): 6674-6682. doi: 10.1021/am5092165

[12] Sun R, Liu M, Lu J, et al. Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy[J]. Nat Commun, 2022, 13(1): 5127. doi: 10.1038/s41467-022-32837-5

[13] Lakkadwala S, Dos Santos Rodrigues B, Sun C, et al. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma[J]. J Controlled Release, 2019, 307: 247-260. doi: 10.1016/j.jconrel.2019.06.033

[14] Lopez-Bertoni H, Kozielski KL, Rui Y, et al. Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival[J]. Nano Lett, 2018, 18(7): 4086-4094. doi: 10.1021/acs.nanolett.8b00390

[15] Pinel S, Thomas N, Boura C, et al. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment[J]. Adv Drug Delivery Rev, 2019, 138: 344-357. doi: 10.1016/j.addr.2018.10.013

[16] Ramalho MJ, Sevin E, Gosselet F, et al. Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment[J]. Int J Pharm, 2018, 545(1-2): 84-92. doi: 10.1016/j.ijpharm.2018.04.062

[17] Chu L, Wang A, Ni L, et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting[J]. Drug Deliv, 2018, 25(1): 1634-1641. doi: 10.1080/10717544.2018.1494226

[18] Gu W, Fan R, Quan J, et al. Intracranial in situ thermosensitive hydrogel delivery of temozolomide accomplished by PLGA-PEG-PLGA triblock copolymer blending for GBM treatment[J]. Polymers, 2022, 14(16): 3368. doi: 10.3390/polym14163368

[19] Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications[J]. J Controlled Release, 2012, 161(2): 505-522. doi: 10.1016/j.jconrel.2012.01.043

[20] Chen X, Gao C. Influences of surface coating of PLGA nanoparticles on immune activation of macrophages[J]. J Mater Chem B, 2018, 6(14): 2065-2077. doi: 10.1039/C7TB03080K

[21] Sun L, Joh DY, Al-Zaki A, et al. Theranostic application of mixed gold and superparamagnetic iron oxide nanoparticle micelles in glioblastoma multiforme[J]. J Biomed Nanotechnol, 2016, 12(2): 347-356. doi: 10.1166/jbn.2016.2173

[22] Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme[J]. J Neuro-Oncol, 2011, 103: 317-324. doi: 10.1007/s11060-010-0389-0

[23] Klein S, Kızaloğlu M, Portilla L, et al. Enhanced in vitro biocompatibility and water dispersibility of magnetite and cobalt ferrite nanoparticles employed as ROS formation enhancer in radiation cancer therapy[J]. Small, 2018, 14(21): 1704111. doi: 10.1002/smll.201704111

[24] Hauser AK, Mitov MI, Daley EF, et al. Targeted iron oxide nanoparticles for the enhancement of radiation therapy[J]. Biomaterials, 2016, 105: 127-135. doi: 10.1016/j.biomaterials.2016.07.032

[25] He C, Jiang S, Jin H, et al. Mitochondrial electron transport chain identified as a novel molecular target of SPIO nanoparticles mediated cancer-specific cytotoxicity[J]. Biomaterials, 2016, 83: 102-114. doi: 10.1016/j.biomaterials.2016.01.010

[26] Li R, He Y, Zhang S, et al. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment[J]. Acta Pharm Sin B, 2018, 8(1): 14-22. doi: 10.1016/j.apsb.2017.11.009

[27] Xuan M, Shao J, Li J. Cell membrane-covered nanoparticles as biomaterials[J]. Natl Sci Rev, 2019, 6(3): 551-561. doi: 10.1093/nsr/nwz037

[28] Oroojalian F, Beygi M, Baradaran B, et al. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy[J]. Small, 2021, 17(12): 2006484. doi: 10.1002/smll.202006484

[29] Fang RH, Kroll AV, Gao W, et al. Cell membrane coating nanotechnology[J]. Adv Mater, 2018, 30(23): 1706759. doi: 10.1002/adma.201706759

[30] Ma J, Dai L, Yu J, et al. Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology[J]. Biomaterials, 2023, 295: 122026.

[31] Ananta JS, Paulmurugan R, Massoud TF. Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation[J]. Neurol Res, 2016, 38(1): 51-59. doi: 10.1080/01616412.2015.1133025

[32] Tang C, Wang Q, Li K, et al. A neutrophil-mimetic magnetic nanoprobe for molecular magnetic resonance imaging of stroke-induced neuroinflammation[J]. Biomater Sci, 2021, 9(15): 5247-5258. doi: 10.1039/D1BM00566A

[33] Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence[J]. Nat Nanotechnol, 2017, 12(7): 692-700. doi: 10.1038/nnano.2017.54

[34] Tang C, Wang C, Zhang Y, et al. Recognition, intervention, and monitoring of neutrophils in acute ischemic stroke[J]. Nano Lett, 2019, 19(7): 4470-4477. doi: 10.1021/acs.nanolett.9b01282

[35] Rybka JD. Radiosensitizing properties of magnetic hyperthermia mediated by superparamagnetic iron oxide nanoparticles (SPIONs) on human cutaneous melanoma cell lines[J]. Rep Pract Oncol Radiother, 2019, 24(2): 152-157. doi: 10.1016/j.rpor.2019.01.002

[36] Wang Z, Zhang F, Shao D, et al. Janus nanobullets combine photodynamic therapy and magnetic hyperthermia to potentiate synergetic anti‐metastatic immunotherapy[J]. Adv Sci, 2019, 6(22): 1901690. doi: 10.1002/advs.201901690

[37] Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance[J]. Pharmacol Res, 2021, 171: 105780.

[38] Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996. doi: 10.1056/NEJMoa043330

[39] Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours[J]. Nat Rev Mater, 2016, 1(5): 16014. doi: 10.1038/natrevmats.2016.14